iTeos Therapeutics

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Our mission is to develop and commercialize novel therapies that modulate both innate and adaptive immune responses to treat cancer and other serious diseases.

Our vision is to become a world-leading immuno-oncology company that creates a lasting legacy of improving and extending patients’ lives with our innovative therapies.

iTeos was named “Company of the Year” in Immuno-oncology at the DED×LIFE festival in 2017 and the team was recognized for its efforts to advance the field of cancer immunotherapy through innovation and collaboration.